INSM
Insmed Incorporated · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.7% ·
share flow -9.5% ·
net new positions -7.1%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.33M | $149.97M | n/a | −2 |
| Q2 2026 | 156 | -6 | 147.06M | $15.68B | +6 | −13 |
| Q1 2026 | 166 | +6 | 152.11M | $24.63B | +9 | −4 |
| Q4 2025 | 159 | -1 | 156.45M | $27.23B | +1 | −1 |
| Q3 2025 | 21 | +1 | 121.03M | $17.43B | +1 | −1 |
| Q2 2025 | 18 | +1 | 70.35M | $7.08B | +2 | −1 |
| Q1 2025 | 14 | -1 | 33.99M | $2.59B | n/a | −1 |
| Q4 2024 | 15 | 0 | 31.46M | $2.17B | +1 | −1 |
| Q3 2024 | 14 | -1 | 23.46M | $1.71B | n/a | −1 |
| Q2 2024 | 15 | n/a | 25.91M | $1.74B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 12.58M | +3.4% | $918.41M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (passive) | 3.81M | +4.7% | $278.43M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (passive) | 1.66M | -5.7% | $120.94M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Adage Capital Partners ✦ | 1.03M | -22.1% | $75.38M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 962.46K | +2.6% | $70.26M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 6 | Two Sigma Investments ✦ | 801.14K | +643.6% | $58.48M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 7 | Marshall Wace ✦ | 771.21K | -38.3% | $56.30M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 8 | Millennium Management ✦ | 564.86K | -52.9% | $41.23M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 9 | Soros Fund Management ✦ | 478.60K | +1.7% | $34.94M | 1.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 336.56K | -57.9% | $24.57M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 11 | Point72 Asset Management ✦ | 315.15K | -63.3% | $23.01M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 66.73K | -76.9% | $4.87M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 13 | AQR Capital Management ✦ | 62.88K | +3.9% | $4.59M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 14 | Duquesne Family Office ✦ | 20.00K | 0.0% | $1.46M | 0.1% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Viking Global Investors | $69.41M | was 0.3% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 664 holders, 192.22M shares, $30.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 25.00K sh · $3.10M
Director · 5.00K sh · $637,650
Officer · 239.85K sh · $31.96M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology